- Revive Therapeutics (RVV) and PharmaTher (PHRM) signed a research collaboration agreement to evaluate the delivery of MDMA using microneedle patch delivery technology
- PharmaTher’s novel MN-Patch can penetrate the outer layer of the skin, enable flexible drug load capacity and combinations, and control-release delivery
- The team completed a non-clinical research study evaluating its delivery. Results will be available in early Q2 2023, intended to support a potential human clinical study
- Revive Therapeutics Ltd. (RVV) was down 3.57 per cent, trading at C$0.13 per share, and PharmaTher (PHRM) was down 8.57 per cent, trading at C$0.16 per share
Revive Therapeutics (RVV), and PharmaTher (PHRM) have signed a research collaboration agreement.
Under the agreement, the companies will evaluate the delivery of MDMA using microneedle patch delivery technology.
PharmaTher’s novel MN-Patch can penetrate the outer layer of the skin, enable flexible drug load capacity and combinations, and control-release delivery. The team completed a non-clinical research study evaluating its delivery. Results will be available in early Q2 2023 to support a potential human clinical study.
Revive’s CEO, Michael Frank, commented that the MDMA microneedle patch will complement his company’s psilocybin programs for mental health and abuse disorders.
“We look forward to advancing the MDMA patch program that could fill the gaps that we believe could offer an advantage to oral MDMA treatments.”
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
PharmaTher Holdings Ltd. (PHRM) is a psychedelics biotech company focused on the research, development, and commercialization of psychedelics, such as ketamine, to treat mental health, neurological and pain disorders.
Revive Therapeutics Ltd. (RVV) was down 3.57 per cent, trading at C$0.13 per share.
PharmaTher (PHRM) was down 8.57 per cent, trading at C$0.16 per share.
